Advertisement
The presentation will be webcast live and may be accessed via a link onthe Sangamo BioSciences website in the Investor Relations sectionhttp://investor.sangamo.com/index.cfm under Events and Presentations. Thepresentation will be archived on the Sangamo website for two weeks after theevent.
Advertisement
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development ofnovel DNA-binding proteins for therapeutic gene regulation and modification.The most advanced ZFP Therapeutic(TM) development program is currently inPhase 2 clinical trials for evaluation of safety and clinical effect inpatients with diabetic neuropathy. Phase 1 clinical trials are ongoing toevaluate a ZFP Therapeutic for peripheral artery disease. Other therapeuticdevelopment programs are focused on cancer and HIV/AIDS, neuropathic pain,nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo'score competencies enable the engineering of a class of DNA-binding proteinsknown as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs thatrecognize a specific DNA sequence Sangamo has created ZFP transcriptionfactors (ZFP TF(TM)) that can control gene expression and, consequently, cellfunction. Sangamo is also developing sequence-specific ZFP Nucleases(ZFN(TM)) for gene modification. Sangamo has established strategicpartnerships with companies outside of the human therapeutic space includingDow AgroSciences, Sigma-Aldrich and several companies applying its ZFPTechnology to enhance the production of protein pharmaceuticals. For moreinformation about Sangamo, visit the company's web site athttp://www.sangamo.com.
This press release may contain forward-looking statements based onSangamo's current expectations. These forward-looking statements include,without limitation, references to the research and development of novel ZFPTFs and applications of Sangamo's ZFP TF technology platform. Actual resultsmay differ materially from these forward-looking statements due to a number offactors, including technological challenges, Sangamo's ability to developcommercially viable products and technological developments by ourcompetitors. See the company's SEC filings, and in particular, the riskfactors described in the company's Annual Report on Form 10-K and its mostrecent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update theforward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
